Literature DB >> 18592348

Microprocessor in controlled transdermal drug delivery of anti-cancer drugs.

N S Chandrashekar1, R H Shobha Rani.   

Abstract

Microprocessor controlled transdermal delivery of anticancer drugs 5-Fluorouracil (5-FU) and 6-Mercaptopurine (6-MP) was developed and in vitro evaluation was done. Drugs were loaded based on the pharmacokinetics parameters. In vitro diffusion studies were carried at different current density (0.0, 0.1, 0.22, 0.50 mA/cm2). The patches were evaluated for the drug content, thickness, weight, folding endurance, flatness, thumb tack test and adhesive properties all were well with in the specification of transdermal patches with elegant and transparent in appearance. In vitro permeation studies through human cadaver skin showed, passive delivery (0.0 mA/cm2) of 6-MP was low. As the current density was progressively increased, the flux also increased. the flux also increased with 0.1 mA/cm2 for 15-20 min, but it was less than desired flux, 0.2 mA/cm2 for 30 min showed better flux than 0.1 mA/cm2 current, but lag time was more than 4 h, 0.5 mA/cm2 current for more than 1 h, flux was >159 microg/cm2 h which was desired flux for 6-MP. 5-FU flux reached the minimum effective concentration (MEC) of 54 microg/cm2 h with 0.5 mA/cm2 current for 30-45 min, drug concentration were within the therapeutic window in post-current phase. We concluded from Ohm's Law that as the resistance decreases, current increases. Skin resistance decrease with increase in time and current, increase in the drug permeation. Interestingly, for all investigated current densities, as soon as the current was switched off, 5-FU and 6-MP flux decreased fairly, but the controlled drug delivery can be achieved by switching the current for required period of time.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18592348     DOI: 10.1007/s10856-008-3510-6

Source DB:  PubMed          Journal:  J Mater Sci Mater Med        ISSN: 0957-4530            Impact factor:   3.896


  14 in total

1.  Enhanced bioavailability of azathioprine compared to 6-mercaptopurine therapy in inflammatory bowel disease: correlation with treatment efficacy.

Authors:  C Cuffari; S Hunt; T M Bayless
Journal:  Aliment Pharmacol Ther       Date:  2000-08       Impact factor: 8.171

2.  Effect of several factors on the mechanical properties of pressure-sensitive adhesives used in transdermal therapeutic systems.

Authors:  D A Dimas; P P Dallas; D D Rekkas; N H Choulis
Journal:  AAPS PharmSciTech       Date:  2000-06-18       Impact factor: 3.246

3.  PREPARATION OF ISOLATED SHEETS OF HUMAN STRATUM CORNEUM.

Authors:  A M KLIGMAN; E CHRISTOPHERS
Journal:  Arch Dermatol       Date:  1963-12

Review 4.  Skin electroporation for transdermal and topical delivery.

Authors:  Anne-Rose Denet; Rita Vanbever; Véronique Préat
Journal:  Adv Drug Deliv Rev       Date:  2004-03-27       Impact factor: 15.470

Review 5.  Microprocessor controlled transdermal drug delivery.

Authors:  J Anand Subramony; Ashutosh Sharma; J B Phipps
Journal:  Int J Pharm       Date:  2006-04-18       Impact factor: 5.875

6.  Electrorepulsion versus electroosmosis: effect of pH on the iontophoretic flux of 5-fluorouracil.

Authors:  V Merino; A López; Y N Kalia; R H Guy
Journal:  Pharm Res       Date:  1999-05       Impact factor: 4.200

Review 7.  Central nervous system leukemia.

Authors:  W A Bleyer
Journal:  Pediatr Clin North Am       Date:  1988-08       Impact factor: 3.278

8.  [Enhanced percutaneous absorption of formoterol furmarate via pulsed iontophoresis. I. Effect of constant current and constant voltage].

Authors:  K Sudeji; M Kawasaki; H Inada; K Katayama; M Kakemi; T Koizumi
Journal:  Yakugaku Zasshi       Date:  1989-10       Impact factor: 0.302

Review 9.  Cholestatic hepatocellular injury with azathioprine: a case report and review of the mechanisms of hepatotoxicity.

Authors:  J Romagnuolo; D C Sadowski; E Lalor; L Jewell; A B Thomson
Journal:  Can J Gastroenterol       Date:  1998-10       Impact factor: 3.522

Review 10.  Clinical pharmacology of 5-fluorouracil.

Authors:  R B Diasio; B E Harris
Journal:  Clin Pharmacokinet       Date:  1989-04       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.